Expertise in
1
conditions

Chiun Y. Hsu

No. 7, Chung Shan South Road, 100, 
TPQ, TW 
Expertise in
1
conditions
No. 7, Chung Shan South Road, 100, 
TPQ, TW 

Overview

Chiun Hsu practices practicing medicine in Taiwan.

Hsu is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Liver Cancer, Hepatitis B, Angiosarcoma of the Liver, and Cholangiocarcinoma (Bile Duct Cancer).

They are actively involved in clinical research, co-authoring 121 peer reviewed articles and participating in 8 clinical trials.

Locations

No. 7, Chung Shan South Road, 100, TPQ, Taiwan
Other Locations
7 Chung Shan South Road, TPQ 10002, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Atezolizumab Plus Bevacizumab for Patients With Advanced Hepatocellular Carcinoma (HCC) and Chronic Hepatitis B Virus (HBV) Infection
Atezolizumab Plus Bevacizumab for Patients With Advanced Hepatocellular Carcinoma (HCC) and Chronic Hepatitis B Virus (HBV) Infection
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2026
Intervention Type: Drug
Study Phase: Not Applicable
A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
A Phase 2, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma
Enrollment Status: Completed
Publish Date: October 26, 2024
Intervention Type: Drug
Study Drug: Tislelizumab
Study Phase: Phase 2
Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
Enrollment Status: Completed
Publish Date: July 08, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma
Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: February 09, 2024
Intervention Type: Drug
Study Drug: GT90001 and Nivolumab
Study Phase: Phase 1/Phase 2
A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma
A Phase I/II Study of CX-4945 in Combination With Gemcitabine and Cisplatin in the Frontline Treatment of Patients With Cholangiocarcinoma
Enrollment Status: Completed
Publish Date: October 22, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer
A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer
Enrollment Status: Completed
Publish Date: August 21, 2019
Intervention Type: Drug
Study Phase: Phase 2
A Phase II Trial of LDK378 as the First or Second-line Therapy in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma
A Phase II Trial of LDK378 as the First or Second-line Therapy in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: April 05, 2018
Intervention Type: Drug
Study Phase: Phase 2
A Phase I Study of TS-1 With Concurrent Radiotherapy Followed by Gemcitabine and TS-1 in Metastatic Pancreatic Cancer (SR-GS Study)
A Phase I Study of TS-1 With Concurrent Radiotherapy Followed by Gemcitabine and TS-1 in Metastatic Pancreatic Cancer (SR-GS Study)
Enrollment Status: Terminated
Publish Date: January 18, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

121 Total Publications

Early Change in Subcutaneous Fat Attenuation on Follow-up CT Provides Prognostic Information Beyond AFP in Advanced Hepatocellular Carcinoma During Immunotherapy.
Early Change in Subcutaneous Fat Attenuation on Follow-up CT Provides Prognostic Information Beyond AFP in Advanced Hepatocellular Carcinoma During Immunotherapy.
Journal: Academic radiology
Published: April 18, 2026

Frequently Asked Questions about Chiun Y. Hsu

Is Chiun Y. Hsu a top-rated expert for Liver Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Chiun Y. Hsu is classified as an Distinguished expert for Liver Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Chiun Y. Hsu participate in research or clinical trials?

Yes. Chiun Y. Hsu has published 121 articles and abstracts on conditions like Liver Cancer. You can view a list of Chiun Y. Hsu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Hsu's expertise for a condition
ConditionClose
      View All 17 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile